A sensitive array-based assay for identifying multiple TMPRSS2:ERG fusion gene variants

Studies of gene fusions in solid tumors are not as extensive as in hematological malignancies due to several technical and analytical problems associated with tumor heterogeneity. Nevertheless, there is a growing interest in the role of fusion genes in common epithelial tumors after the discovery of recurrent TMPRSS2:ETS fusions in prostate cancer. Among all of the reported fusion partners in the ETS gene family, TMPRSS2:ERG is the most prevalent one. Here, we present a simple and sensitive microarray-based assay that is able to simultaneously determine multiple fusion variants with a single RT–PCR in impure RNA specimens. The assay detected TMPRSS2:ERG fusion transcripts with a detection sensitivity of <10 cells in the presence of more than 3000 times excess normal RNA, and in primary prostate tumors having no >1% of cancer cells. The ability to detect multiple transcript variants in a single assay is critically dependent on both the primer and probe designs. The assay should facilitate clinical and basic studies for fusion gene screening in clinical specimens, as it can be readily adapted to include multiple gene loci.

[1]  T. Tammela,et al.  TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis , 2008, Clinical Cancer Research.

[2]  M. Rubin.  Targeted therapy of cancer: new roles for pathologists—prostate cancer , 2008, Modern Pathology.

[3]  R. Shah,et al.  Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.

[4]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[5]  Gratien G. Prefontaine,et al.  Developmentally Regulated Activation of a SINE B2 Repeat as a Domain Boundary in Organogenesis , 2007, Science.

[6]  Y Pawitan,et al.  TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.

[7]  B. Jordan.  DNA microarrays in the clinic: how soon, how extensively? , 2007, BioEssays : news and reviews in molecular, cellular and developmental biology.

[8]  Junia V. Melo,et al.  Chronic myeloid leukaemia as a model of disease evolution in human cancer , 2007, Nature Reviews Cancer.

[9]  Debashis Ghosh,et al.  Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer , 2007, Modern Pathology.

[10]  R. Eeles,et al.  Diversity of TMPRSS2-ERG fusion transcripts in the human prostate , 2007, Oncogene.

[11]  Yu-Tseung Liu,et al.  A Novel Approach for Determining Cancer Genomic Breakpoints in the Presence of Normal DNA , 2007, PloS one.

[12]  T. Szczepański.  Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? , 2007, Leukemia.

[13]  B. Johansson,et al.  The impact of translocations and gene fusions on cancer causation , 2007, Nature Reviews Cancer.

[14]  J. Brooks,et al.  A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis , 2007, Modern Pathology.

[15]  S. Leung,et al.  Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers , 2007, Journal of Clinical Pathology.

[16]  Yang Liu,et al.  Panmicrobial Oligonucleotide Array for Diagnosis of Infectious Diseases , 2007, Emerging infectious diseases.

[17]  L. Klotz,et al.  Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression , 2007, Cancer biology & therapy.

[18]  G. Jenster,et al.  TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. , 2006, Cancer research.

[19]  O. Kallioniemi,et al.  TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. , 2006, Cancer research.

[20]  Lei Wang,et al.  Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. , 2006, Neoplasia.

[21]  R. Henrique,et al.  TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. , 2006, Neoplasia.

[22]  Michael Ittmann,et al.  Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.

[23]  J. Tchinda,et al.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.

[24]  J. Schalken,et al.  THE TMPRSS2-ERG FUSION GENE CAN BE FOUND IN URINARY SEDIMENTS AFTER DRE , 2006 .

[25]  I. Panagopoulos,et al.  Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. , 2006, Genes, chromosomes & cancer.

[26]  A. Scott,et al.  TARGETING OF TNF TO CLEAR CELL RENAL CELL CARCINOMA , 2006 .

[27]  Simona Soverini,et al.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.

[28]  A. Evans,et al.  Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. , 2006, Neoplasia.

[29]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[30]  Arul M Chinnaiyan,et al.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. , 2006, Cancer research.

[31]  J. Cayuela,et al.  A diagnostic biochip for the comprehensive analysis of MLL translocations in acute leukemia , 2004, Leukemia.

[32]  J. Lieb,et al.  ChIP-chip: considerations for the design, analysis, and application of genome-wide chromatin immunoprecipitation experiments. , 2004, Genomics.

[33]  J. Wang-Rodriguez,et al.  In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Mirzabekov,et al.  Clinical screening of gene rearrangements in childhood leukemia by using a multiplex polymerase chain reaction-microarray approach. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  James M. Eldred,et al.  Viral Discovery and Sequence Recovery Using DNA Microarrays , 2003, PLoS biology.

[36]  J. Rowley,et al.  Screening and quantification of multiple chromosome translocations in human leukemia. , 2003, Clinical chemistry.

[37]  David Botstein,et al.  Promoter-specific binding of Rap1 revealed by genome-wide maps of protein–DNA association , 2001, Nature Genetics.

[38]  K. Pienta,et al.  VCaP, a cell-based model system of human prostate cancer. , 2001, In vivo.

[39]  M. Ladanyi,et al.  Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. , 1999, Cancer research.

[40]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  W. Gerald,et al.  EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Rowley,et al.  A method for the rapid sequence-independent amplification of microdissected chromosomal material. , 1992, Genomics.

[43]  A. Chinnaiyan,et al.  Recurrent gene fusions in prostate cancer , 2008, Nature Reviews Cancer.

[44]  K. Garner,et al.  Rapid detection of leukemia-associated translocation fusion genes using a novel combined RT-PCR and flow cytometric method , 2002, Leukemia.

[45]  A. Mirzabekov,et al.  Identification of chromosomal translocations in leukemias by hybridization with oligonucleotide microarrays. , 2002, Haematologica.

[46]  P. Brown,et al.  DNA arrays for analysis of gene expression. , 1999, Methods in enzymology.